FDA — authorised 5 March 2024
- Application: BLA761362
- Marketing authorisation holder: SANDOZ INC
- Local brand name: WYOST
- Indication: INJECTABLE — SUBCUTANEOUS
- Status: approved
FDA authorised JUBBONTI on 5 March 2024
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA authorised it on 5 March 2024; FDA has authorised it.
SANDOZ INC holds the US marketing authorisation.